No evidence for increased platelet activation in patients with hepatitis B- or C-related cirrhosis and hepatocellular carcinoma

Thrombosis Research

Volumn 135, Issue 2, 2015, Pages 292-297

  Alkozai, Edris M ^a   Porte, Robert J ^a   Adelmeijer, Jelle ^a   Zanetto, Alberto ^b   Simioni, Paolo ^b   Senzolo, Marco ^b   Lisman, Ton ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY HOSPITAL OF PADOVA   (Italy)

Author keywords

ADAMTS13; Cirrhosis; Hepatocellular carcinoma; P selectin; Platelet; Von Willebrand factor

Indexed keywords

ANTINEOPLASTIC AGENT; PADGEM PROTEIN; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ADULT; ARTICLE; BLOOD SAMPLING; CANCER SURGERY; CHEMOEMBOLIZATION; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FEMALE; FLOW CYTOMETRY; HEMOSTASIS; HEPATITIS B; HEPATITIS C; HUMAN; IN VITRO STUDY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MALE; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN CLEAVAGE; RADIOFREQUENCY ABLATION; RADIOSURGERY; THROMBOCYTE ACTIVATION; THROMBOCYTE COUNT; BLOOD; LIVER TUMOR; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; RISK FACTOR; VIROLOGY;

ADULT; CARCINOMA, HEPATOCELLULAR; CROSS-SECTIONAL STUDIES; FEMALE; HEPATITIS B; HEPATITIS C; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PLATELET ACTIVATION; RISK FACTORS;

EID: 84921451670     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2014.11.016     Document Type: Article

References (50)

1. Prandoni P, Lensing AW, Buller HR, Cogo A, Prins MH, Cattelan AM, et al. Deep-vein thrombosis and the incidence of subsequent symptomatic cancer. N Engl J Med 1992;327:1128-33.
2. Timp JF, Braekkan SK, Versteeg HH, Cannegieter SC. Epidemiology of cancer associated venous thrombosis. Blood 2013;122:1712-23.
3. Gomes M, Khorana AA. Risk assessment for thrombosis in cancer. Semin Thromb Hemost 2014;40:319-24.
4. Piccioli A, Falanga A, Baccaglini U, Marchetti M, Prandoni P. Cancer and venous thromboembolism. Semin Thromb Hemost 2006;32:694-9.
5. Falanga A, Donati MB. Pathogenesis of thrombosis in patients with malignancy. Int J Hematol 2001;73:137-44.
6. Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 2008; 111:4902-7.
7. Sallah S, Wan JY, Nguyen NP. Venous thrombosis in patients with solid tumors: determination of frequency and characteristics. Thromb Haemost 2002;87:575-9.
8. Kroger K, Weiland D, Ose C, Neumann N, Weiss S, Hirsch C, et al. Risk factors for venous thromboembolic events in cancer patients. Ann Oncol 2006;17:297-303.
9. Hwang SJ, Luo JC, Li CP, Chu CW,Wu JC, Lai CR, et al. Thrombocytosis: a paraneoplastic syndrome in patients with hepatocellular carcinoma.World J Gastroenterol 2004;10:2472-7.
10. Stone RL, Nick AM, McNeish IA, Balkwill F, Han HD, Bottsford-Miller J, et al. Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med 2012;366:610-8.
11. Simanek R, Vormittag R, Ay C, Alguel G, Dunkler D, Schwarzinger I, et al. High platelet count associated with venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS). J Thromb Haemost 2010;8:114-20.
12. Gay LJ, Felding-Habermann B. Contribution of platelets to tumour metastasis. Nat Rev Cancer 2011;11:123-34.
13. Sitia G, Aiolfi R, Di Lucia P, Mainetti M, Fiocchi A, Mingozzi F, et al. Antiplatelet therapy prevents hepatocellular carcinoma and improves survival in a mouse model of chronic hepatitis B. Proc Natl Acad Sci U S A 2012;109:E2165-72.
14. Ho-Tin-Noe B, Goerge T, Wagner DD. Platelets: guardians of tumor vasculature. Cancer Res 2009;69:5623-6.
15. Rothwell PM, Fowkes FG, Belch JF, Ogawa H, Warlow CP, Meade TW. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 2011;377:31-41.
16. Rothwell PM, Price JF, Fowkes FG, Zanchetti A, Roncaglioni MC, Tognoni G, et al. Short-term effects of daily aspirin on cancer incidence, mortality, and nonvascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet 2012;397:1602-12.
17. Rothwell PM, Wilson M, Price JF, Belch JF, Meade TW, Mehta Z. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet 2012;397:1591-601.
18. Algra AM, Rothwell PM. Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncol 2012;13:518-27.
19. Cho MS, Bottsford-Miller J, Vasquez HG, Stone R, Zand B, Kroll MH, et al. Platelets increase the proliferation of ovarian cancer cells. Blood 2012;120:4869-72.
20. Italiano Jr JE, Richardson JL, Patel-Hett S, Battinelli E, Zaslavsky A, Short S, et al. Angiogenesis is regulated by a novel mechanism: pro- and antiangiogenic proteins are organized into separate platelet alpha granules and differentially released. Blood 2008;111:1227-33.
21. Nieswandt B, Hafner M, Echtenacher B, Mannel DN. Lysis of tumor cells by natural killer cells in mice is impeded by platelets. Cancer Res 1999;59:1295-300.
22. Schumacher D, Strilic B, Sivaraj KK, Wettschureck N, Offermanns S. Platelet-derived nucleotides promote tumor-cell transendothelial migration and metastasis via P2Y2 receptor. Cancer Cell 2013;24:130-7.
23. Riedl J, Pabinger I, Ay C. Platelets in cancer and thrombosis. Hamostaseologie 2014;34:54-62.
24. Witters P, Freson K, Verslype C, Peerlinck K, Hoylaerts M, Nevens F, et al. Review article: blood platelet number and function in chronic liver disease and cirrhosis. Aliment Pharmacol Ther 2008;27:1017-29.
25. Violi F, Basili S, Raparelli V, Chowdary P, Gatt A, Burroughs AK. Patientswith liver cirrhosis suffer from primary haemostatic defects? Fact or fiction? J Hepatol 2011;55:1415-27.
26. Lisman T, Adelmeijer J, Janssen HLA, de Groot PG, Leebeek FWG. No evidence for an intrinsic plate-let defect in patients with liver cirrhosis - studies under flow conditions. J Thromb Haemost 2006;4:2070-2.
27. Basili S, Raparelli V, Riggio O, Merli M, Carnevale R, Angelico F, et al. NADPH oxidase-mediated platelet isoprostane over-production in cirrhotic patients: implication for platelet activation. Liver Int 2011;31:1533-40.
28. Kokame K, Nobe Y, Kokubo Y, Okayama A, Miyata T. FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay. Br J Haematol 2005;129:93-100.
29. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973;60:646-9.
30. Lisman T, Bongers TN, Adelmeijer J, Janssen HL, de Maat MP, de Groot PG, et al. Elevated levels of von Willebrand Factor in cirrhosis support platelet adhesion despite reduced functional capacity. Hepatology 2006;44:53-61.
31. Hugenholtz GC, Adelmeijer J, Meijers JC, Porte RJ, Stravitz RT, Lisman T. An unbalance between von Willebrand factor and ADAMTS13 in acute liver failure: implications for hemostasis and clinical outcome. Hepatology 2013;58:752-61.
32. Roselli M, Mineo TC, Martini F, Mariotti S, Ambrogi V, Spila A, et al. Soluble selectin levels in patients with lung cancer. Int J Biol Markers 2002;17:56-62.
33. Ferroni P, Roselli M, Martini F, D'Alessandro R, Mariotti S, Basili S, et al. Prognostic value of soluble P-selectin levels in colorectal cancer. Int J Cancer 2004;111:404-8.
34. Blann AD, Gurney D, Wadley M, Bareford D, Stonelake P, Lip GY. Increased soluble P-selectin in patients with haematological and breast cancer: a comparison with fibrinogen, plasminogen activator inhibitor and von Willebrand factor. Blood Coagul Fibrinolysis 2001;12:43-50.
35. Caine GJ, Lip GY, Stonelake PS, Ryan P, Blann AD. Platelet activation, coagulation and angiogenesis in breast and prostate carcinoma. Thromb Haemost 2004;92:185-90.
36. Starlinger P, Moll HP, Assinger A, Nemeth C, Hoetzenecker K, Gruenberger B, et al. Thrombospondin-1: a unique marker to identify in vitro platelet activation when monitoring in vivo processes. J Thromb Haemost 2010;8:1809-19.
37. Gong L, Cai Y, Zhou X, Yang H. Activated platelets interact with lung cancer cells through P-selectin glycoprotein ligand-1. Pathol Oncol Res 2012;18:989-96.
38. Mantur M, Kemona H, Kozlowski R, Kemona-Chetnik I. Effect of tumor stage and nephrectomy on CD62P expression and sP-selectin concentration in renal cancer. Neoplasma 2003;50:262-5.
39. Erpenbeck L, Schon MP. Deadly allies: the fatal interplay between platelets and metastasizing cancer cells. Blood 2010;115:3427-36.
40. Lisman T, Porte RJ. The role of platelets in liver inflammation and regeneration. Semin Thromb Hemost 2010;36:170-4.
41. Alkozai EM, Porte RJ, Adelmeijer J, Zanetto A, Simioni P, Senzolo M, et al. Levels of angiogenic proteins in plasma and platelets are not different between patients with hepatitis B/C-related cirrhosis and patients with cirrhosis and hepatocellular carcinoma. Platelets 2014 (in press).
42. Lisman T, Porte RJ. Pitfalls in assessing platelet activation status in patients with liver disease. Liver Int 2012;32:1027.
43. Laffi G, Cominelli F, Ruggiero M, Fedi S, Chiarugi VP, La Villa G, et al. Altered platelet function in cirrhosis of the liver: impairment of inositol lipid and arachidonic acid metabolism in response to agonists. Hepatology 1988;8:1620-6.
44. Laffi G, Marra F, Gresele P, Romagnoli P, Palermo A, Bartolini O, et al. Evidence for a storage pool defect in platelets from cirrhotic patients with defective aggregation. Gastroenterology 1992;103:641-6.
45. Laffi G, Marra F, Failli P, Ruggiero M, Cecchi E, Carloni V, et al. Defective signal transduction in platelets from cirrhotics is associated with increased cyclic nucleotides. Gastroenterology 1993;105:148-56.
46. Schellerer VS, Mueller-Bergh L, Merkel S, Zimmermann R, Weiss D, Schlabrakowski A, et al. The clinical value of von Willebrand factor in colorectal carcinomas. Am J Transl Res 2011;3:445-53.
47. Gadducci A, Baicchi U, Marrai R, Del Bravo B, Fosella PV, Facchini V. Pretreatment plasma levels of fibrinopeptide-A (FPA), D-dimer (DD), and von Willebrand factor (vWF) in patients with ovarian carcinoma. Gynecol Oncol 1994;53:352-6.
48. Zietek Z, Iwan-Zietek I, Paczulski R, Kotschy M, Wolski Z. von Willebrand factor antigen in blood plasma of patients with urinary bladder carcinoma. Thromb Res 1996;83:399-402.
49. Mannucci PM, Canciani MT, Forza I, Lussana F, Lattuada A, Rossi E. Changes in health and disease of the metalloprotease that cleaves von Willebrand factor. Blood 2001;98:2730-5.
50. Ikeda H, Tateishi R, Enooku K, Yoshida H, Nakagawa H, Masuzaki R, et al. Prediction of hepatocellular carcinoma development by plasma ADAMTS13 in chronic hepatitis B and C. Cancer Epidemiol Biomarkers Prev 2011;20:2204-11.